Plate Nº 60 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Elevated C-Reactive Protein Linked to Higher Heart Failure and Mortality Risk
A multinational study of 64,743 adults ages 40-80 found that elevated C-reactive protein raised heart failure risk by 34% and all-cause mortality by 90%. Published in 2026.
By James Calloway3 min read659 words
In brief
- Study analyzed 64,743 adults ages 40 to 80 across multiple countries using electronic health records
- Elevated CRP raised heart failure risk by 34% (HR 1.34) and all-cause mortality risk by 90% (HR 1.90)
- Both reduced and preserved ejection fraction heart failure showed elevated risk (HR 1.53 and 1.44)
- Elevated CRP was defined as 3.1–10.0 mg/L; low CRP was defined as 0.1–3.0 mg/L
- Published in the International Journal of Cardiology in 2026 (DOI: 10.1016/j.ijcard.2026.134934)
A multinational study of 64,743 adults found that persistently elevated C-reactive protein (CRP), a blood marker of inflammation, raised the risk of developing heart failure by 34% and all-cause mortality by 90%.
The findings appeared online in the International Journal of Cardiology. The research team, led by Matteo Busti of the Université de Lorraine in Nancy, France, drew on electronic health records from adults aged 40 to 80 who carried at least two cardiovascular risk factors and had two or more CRP readings in the same range.
What did the researchers measure?
CRP is a protein the liver releases in response to inflammation. Doctors routinely measure it in milligrams per liter (mg/L). Levels between 0.1 and 3.0 mg/L count as low; levels between 3.1 and 10.0 mg/L signal low-grade, persistent inflammation. Anything above 10 mg/L usually points to an acute infection.
The team split participants into two matched groups of 19,547 each: one with low CRP and one with elevated CRP. Matching means the groups had comparable ages, body-mass indexes, and other baseline characteristics, which helps isolate the effect of CRP.
How big was the added risk?
After follow-up, participants with elevated CRP faced:
- A 34% higher risk of incident heart failure (hazard ratio 1.34)
- A 90% higher risk of all-cause death (hazard ratio 1.90)
- A 49% higher risk of the combined endpoint (hazard ratio 1.49)
A hazard ratio describes how much more (or less) likely an event is in one group compared with another over a given period. A hazard ratio of 1.34 means the elevated-CRP group was 1.34 times as likely to develop the condition.
Did the type of heart failure matter?
Heart failure comes in two main forms. One, called heart failure with reduced ejection fraction, happens when the heart's main pumping chamber weakens. The other, heart failure with preserved ejection fraction, occurs when the muscle stiffens and cannot fill properly. Ejection fraction measures the share of blood the left ventricle pushes out with each beat.
The researchers found that elevated CRP tracked with both forms:
- Reduced ejection fraction — hazard ratio 1.53
- Preserved ejection fraction — hazard ratio 1.44
Who was affected most?
An exploratory subgroup analysis hinted that participants without obesity saw a stronger link between elevated CRP and adverse outcomes than those with obesity. The authors called this finding exploratory, meaning it was not the main focus of the study and needs confirmation.
What does this mean for patients?
The authors stopped short of recommending routine CRP testing for heart-failure screening. They framed their conclusions as a signal worth more research, not as a clinical guideline.
"These findings may suggest the prognostic relevance of persistent CRP elevation and warrant further investigation of the relationship between low-grade inflammation and heart failure development," the authors wrote.
In other words, persistent low-grade inflammation appears to carry prognostic weight — meaning it can help predict future health events — but the exact mechanism linking CRP to heart failure remains unclear.
What are the study's limits?
The team used routine electronic health records, which vary by country and clinic. CRP was measured as part of normal care rather than on a fixed schedule, so the timing of blood draws differed between patients.
Several authors disclosed financial ties to the biopharmaceutical industry, a common but worth-noting disclosure in cardiovascular research.
The study also measured association, not causation: it showed that elevated CRP tracks with worse outcomes, but it did not prove that lowering CRP would prevent heart failure.
What's next?
The authors frame the work as a call for further investigation into how low-grade inflammation drives heart-failure development. They do not yet recommend routine CRP screening for prevention, and clinical guidelines will need stronger evidence — ideally from trials that track whether lowering inflammation reduces heart-failure cases — before changing practice.
via Medical Xpress (Source)
More from James Calloway
Show full bio
Staff writer covering marketplaces and e-commerce at SciBeat.
205 articles
Nearby plates
- Chronic Inflammation Raises Heart Attack Risk by 43%, Study Finds
- Blood Cell Ratio Predicts Disease Risk a Decade Ahead
- High IgA Levels Identify a High-Risk Subtype of Fatty Liver Disease
- Gut Inflammation Can Damage the Heart — Through Microbes and Immune Cells
- Bodies Show Decline Years Before Heart Attacks and Strokes Strike